Study Finds 1 in 6 Patients with Cancer Experience “Long-Haul” COVID-19

TOP - March 2022 Vol 15, No 2 - COVID-19 & Cancer

According to data from a European registry, approximately 1 in 6 patients with cancer who recovered from COVID-19 infection experienced long-term sequelae (ie, “long-haul” COVID-19), placing them at increased risk for death or discontinuation of anticancer treatment. These results were presented by Alessio Cortellini, MD, Consulting Medical Oncologist and Visiting Researcher, Department of Surgery and Cancer, Imperial College, London, England, and Researcher, Department of Biotechnology and Applied Clinical Sciences, University of L’Aquila, Italy, at the virtual European Society for Medical Oncology Congress 2021.

“It is known that 13% to 60% of COVID-19 patients in the general population can experience long-term sequelae, and 60% to 80% of patients with cancer outlive COVID. But there are unanswered questions about the long-term impact of COVID on patients with cancer that this study sought to address,” Dr Cortellini stated.

Study Details

The OnCOVID registry gathered data on a total of 2795 patients with cancer who were treated at 35 different institutions across 6 European countries from February 2020 to February 2021. Dr Cortellini presented results from 1557 patients with cancer who underwent reassessment after they recovered from COVID-19 to characterize the prevalence and impact of COVID-19 sequelae, and whether systemic anticancer therapy could be resumed.

At a median post–COVID-19 follow-up of 128 days, long-term sequelae were associated with a 76% increase in the risk for death in an analysis adjusted for sex, age, comorbidities, tumor characteristics, anticancer therapy, and COVID-19 severity.

Among the 1557 patients with cancer who had recovered from COVID-19, 234 (15%) suffered at least 1 post–COVID-19 sequelae. The most frequently reported sequelae included respiratory symptoms (49.6%), fatigue (41%), neurocognitive issues (7.3%), and weight loss (5.6%).

Factors associated with an increased risk for long-haul COVID-19 included being male, age ≥65 years, the presence of ≥2 comorbidities, current or former smoking history, and increased rates of previous complicated COVID-19, requiring therapy for COVID-19, and requiring hospitalization for COVID-19.

Of the 471 patients who were being treated with systemic anticancer therapy at the time of COVID-19 diagnosis, long-haul COVID-19 was more prevalent among those who discontinued anticancer care. When patients were reassessed after COVID-19, 14.8% required permanent discontinuation of cancer treatment, which was associated with a 3.5-fold increase in the risk for death. The most common reason for discontinuation of anticancer therapy was worsening performance status, which was reported in 61.3% of patients.

Among patients who required dose adjustments and resumed anticancer therapy (37.8%), survival was not compromised. The main factors that led to dose or regimen adjustments were avoiding hospital attendance (25.8%), immunosuppression (50%), or adverse events (19.1%). Anticancer therapy was unchanged in 9.6% of patients post–COVID-19.

“OnCOVID data suggest that improved awareness, prevention, recognition, and early treatment of COVID-19 sequelae in patients with cancer are important steps toward optimal management,” Dr Cortellini concluded.

Related Items
Sacituzumab plus Pembrolizumab Shows Encouraging Antitumor Activity in Metastatic Urothelial Cancer
Patricia Stewart
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
Circulating Tumor DNA Profiling May Result in Improved Detection and Treatment of CNS Lymphoma
Patricia Stewart
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASH 2021 Highlights
Pembrolizumab plus Chemotherapy Prolongs Survival in Patients with Triple-Negative Breast Cancer and PD-L1 Combined Positive Score ≥10
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in SABCS
Study Shows mRNA COVID-19 Vaccine Safe and Effective in Patients with Cancer Receiving Active Treatment
Charlie Dawson
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in COVID-19 & Cancer
Adagrasib Shows Promising Activity in Patients with KRASᴳ¹²ᶜ-Mutated Metastatic Colorectal Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Colorectal Cancer
Pilot Program Highlights Benefits of Advance Care Planning During the COVID-19 Pandemic
Charlie Dawson
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in COVID-19 & Cancer
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Abiraterone Added to Androgen-Deprivation Therapy Significantly Improves Metastasis-Free Survival in Patients with High-Risk Prostate Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Prostate Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
Results from CAPTURE Trial Support Third COVID-19 Vaccine Dose for Some Patients with Cancer
William King
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in COVID-19 & Cancer
Last modified: March 30, 2022